ArticleFrontiers in endocrinology2026
Maternal obesity and inadequate gestational weight gain disrupts placental dopaminergic signaling: impact on infant neurodevelopment.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The maternal-fetal axis plays a critical role in human development. Obesity during pregnancy may be associated with alterations in this axis, particularly the placental dopaminergic signaling, potentially affecting infant neurodevelopment. Methods: Participants (n=35) from the OBESO cohort (Mexico City) were classified by pregestational BMI as normal weight (n=20) or obese (n=15). Clinical and anthropometric variables of the mother-infant dyads were recorded. Neurodevelopment was evaluated in one-month-old infants using the Bayley-III Scales and classified as normal or altered (score ≤7 in any domain). Placental dopamine (DA) concentrations were quantified by ELISA and correlated with neurodevelopmental status. A subset of samples was analyzed by Western blot to explore the expression of key dopaminergic components: tyrosine hydroxylase (TH), catechol-O-methyltransferase (COMT), vesicular monoamine transporter 2 (VMAT2), organic cation transporter 3 (OCT3), dopamine transporter (DAT), and dopamine receptor D2 (DRD2). Results: Reduced placental DA concentrations, together with altered expression of key dopaminergic elements characterized by increased COMT and DAT, and decreased VMAT2, were observed in association with maternal obesity, inadequate gestational weight gain, and altered infant neurodevelopment. Conclusions: This study provides exploratory evidence that maternal obesity and inadequate GWG may be associated with early alterations in the intrauterine metabolic and neuroendocrine environment, including changes in the placental dopaminergic system. Differences in the expression of COMT, DAT, and VMAT2, together with lower placental DA concentrations, which may be linked to early neurodevelopmental variability in infants. Overall, the results suggest a potential relationship between maternal metabolic status and placental neuroendocrine pathways, warranting further investigation in larger and longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.